(Reuters) -Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.
One of the devices, known as Lingo, is a consumer biowearable, designed for consumers 18 years and older who are looking to improve their overall health and wellness.
The second device, Libre Rio, is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
Abbott did not immediately respond to Reuters request for comment on pricing and availability.
In March, the health regulator cleared Dexcom’s Stelo, making it the first continuous glucose monitor to be available over the counter.
(Reporting by Sriparna Roy and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Comments